How a deal clears the screen and still fails the refinance

The maturity wall is a sorting event

The Mortgage Bankers Association put the figure out at its 2026 Commercial Multifamily Finance Convention: 17% of roughly $5.0 trillion in outstanding commercial mortgages, $875bn, comes due this year¹. That is the year’s largest single refinancing test, and it lands on owners and lenders at once.

$875bn · 17% of outstanding US CRE mortgage debt maturing in 2026¹

The number is not a fresh alarm. It is down 9% from the $957bn scheduled to mature in 2025², and that 2025 figure – 20% of a $4.8 trillion book – came from the same servicer-survey methodology, which gives 2026 a real year-over-year baseline rather than a scare line³.

That methodology matters because it is not a secondary summary. The MBA collects the data directly from the loan servicers on when their loans mature⁴, and calls its annual maturity report its most comprehensive assessment of the subject⁵. When I screen against this, I am screening against the closest thing to a primary count that exists⁶.

So the wall is real and the wall is knowable. What it does not tell me is which of those loans refinance and which do not. That is the sort I have to run myself.

The structural test the summary page skips

The whole screen reduces to one binary: can this loan refinance or extend? If not, it must resolve through recapitalisation or a sale⁷. Everything on the summary page – occupancy, in-place cash flow – sits upstream of that question and answers none of it.

Risk concentrates in a specific stack. It rises where the original loan-to-value ran above 70%, where the loan was written between 2019 and 2022, and where current debt service or value no longer supports a takeout⁸.

On top of that sits the gap test:

1. A refinancing gap above 20% of the outstanding balance is the tell. It says the borrower needs fresh equity or a lender concession; a plain-vanilla refinance will not suffice⁹.

None of this shows on a surface read. A building can be full, paying, and still fail every line of that stack – which is exactly the deal that looks right and is not.

My own work changes register here. In my first round a deal either clears the surface or it does not. In my second round I stop asking whether it looks good and start asking whether it survives – and if it does not survive, what the worst case is, what the recovery rate is, which target investor the deal is even for, and how high the placement probability is.

Of those, the recovery rate is the one that counts. Everything else in the second round is context around that single figure; the rest of the second round exists to price it.

I will be plain about the limit here. I found no checkable source that gives a single recovery rate for this exact subgroup – occupied, cash-flowing loans that pass the surface and fail the LTV/refi-gap test. So I model the recovery rate deal by deal in my own practice; I do not have a market-wide number for it, and I will not manufacture one.

What happens after the failure is the part worth pricing

A failed refinance test does not by itself force a sale. The mechanisms that turn a maturing loan into a distressed-sale candidate are portfolio concentration and weak liquidity at the sponsor level, amplified by thin lender relationships¹⁰. Absent those, a loan can fail the stack and still be worked out quietly.

Lender posture is the other lever. A lender already carrying elevated loss reserves is more likely to accept a discounted resolution than one still holding out for par¹¹. The same failed loan resolves at very different levels depending on which side of that line the lender sits.

Office is the most cited distress pocket, but the trade coverage is careful to frame the weakness as broader than one sector¹². I read that as a warning against screening for a sector when the failure is structural.

Now the honest gaps, in my own words. On which investor type buys a low-recovery deal, I found no named taxonomy in the sourced material – so I work from my own practice, where the buyer I model for is an institutional investor seeking a stable return. The tension is built in: a low recovery rate is precisely what makes that buyer unlikely, which is the same thing as saying placement probability is low. The recovery rate is not the only factor, but it is the one that decides whether the deal has a home.

On how institutions treat high-LTV, wide-gap deals as a matter of documented policy, I found nothing sourced I can stand on. And on how much of the $875bn actually sits above 70% LTV or above a 20% gap, I found no aggregate estimate at all. The stack tells me where to look; it does not size the wall for me.

The strongest version of the other side

A maturity wall is not automatically a distress wall. Many borrowers refinance or inject equity; others extend while waiting for fundamentals to recover – and that is the counter-read I take most seriously¹³.

There are good reasons to sit still. A supply-constrained submarket with real demand drivers can justify patience even when occupancy or NOI is temporarily impaired, which weakens any simple “maturity equals distress” screen¹⁴.

And plenty of near-term maturities clear through sponsor support rather than a forced sale. The mere presence of a 2026 maturity does not, on its own, identify a mispriced deal¹⁵. If my screen flags a loan as distressed on the calendar alone, my screen is wrong.

The consequence

The anti-pattern is not caught at pass or fail. The screen that clears occupancy and cash flow is not the one that tells you whether a loan refinances – the LTV/refi-gap stack is, and what happens after it fails is the only part worth pricing. A deal that survives to the second round is not the interesting case; the deal that passes the surface and dies on the stack is.

And this test recurs. According to one industry summary, an estimated $652bn matures in 2027, which extends the refinancing burden well past this year’s wall¹⁶. Whatever the surface screen misses in 2026, it will get a second chance to miss in 2027.

This is observation from my own desk, not advice. Nothing here is a recommendation to buy, hold, or sell any asset; the figures I have sourced are cited, the ones I have not I have flagged as gaps, and the second-round process is my own practice rather than a market standard. The decision, as always, stays with the reader.